Pacira BioSciences Inc

For the period ended Jun 30, 2024. Filed Jul 30, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Jul 30, 2024

PCRX$36.49+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND 2023

Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome
Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total
Balance at March 31, 2024	46,517	—	$47	$—	$989,780	$(97,817)	$152	$892,162
Vested restricted stock units	381	—	—	—	—	—	—	—
Common stock withheld for employee withholding tax liabilities on vested restricted stock units	—	—	—	—	(378)	—	—	(378)
Common stock issued under employee stockpurchase plan	56	—	—	—	1,364	—	—	1,364
Stock-based compensation	—	—	—	—	12,524	—	—	12,524
Purchase of treasury stock, inclusive of excise tax	—	(837)	—	(25,121)	—	—	—	(25,121)
Purchase of capped call transaction, net of tax	—	—	—	—	(20,112)	—	—	(20,112)
Other comprehensive loss (Note 10)	—	—	—	—	—	—	(47)	(47)
Net income	—	—	—	—	—	18,886	—	18,886
Balance at June 30, 2024	46,954	(837)	$47	$(25,121)	$983,178	$(78,931)	$105	$879,278

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss
Shares · Amount · Total
Balance at March 31, 2023	45,970	$46	$936,419	$(168,287)	$(137)	$768,041
Exercise of stock options	50	—	1,580	—	—	1,580
Vested restricted stock units	339	—	—	—	—	—
Common stock issued under employee stockpurchase plan	50	—	1,672	—	—	1,672
Stock-based compensation	—	—	10,955	—	—	10,955
Other comprehensive loss (Note 10)	—	—	—	—	(36)	(36)
Net income	—	—	—	25,763	—	25,763
Balance at June 30, 2023	46,409	$46	$950,626	$(142,524)	$(173)	$807,975

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome
Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total
Balance at December 31, 2023	46,481	—	$46	$—	$976,633	$(106,796)	$247	$870,130
Vested restricted stock units	417	—	1	—	—	—	—	1
Common stock withheld for employee withholding tax liabilities on vested restricted stock units	—	—	—	—	(382)	—	—	(382)
Common stock issued under employee stockpurchase plan	56	—	—	—	1,364	—	—	1,364
Stock-based compensation	—	—	—	—	25,675	—	—	25,675
Purchase of treasury stock, inclusive of excise tax	—	(837)	—	(25,121)	—	—	—	(25,121)
Purchase of capped call transaction, net of tax	—	—	—	—	(20,112)	—	—	(20,112)
Other comprehensive loss (Note 10)	—	—	—	—	—	—	(142)	(142)
Net income	—	—	—	—	—	27,865	—	27,865
Balance at June 30, 2024	46,954	(837)	$47	$(25,121)	$983,178	$(78,931)	$105	$879,278

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss
Shares · Amount · Total
Balance at December 31, 2022	45,928	$46	$924,095	$(148,751)	$(380)	$775,010
Exercise of stock options	62	—	1,914	—	—	1,914
Vested restricted stock units	369	—	—	—	—	—
Common stock issued under employee stockpurchase plan	50	—	1,672	—	—	1,672
Stock-based compensation	—	—	22,945	—	—	22,945
Other comprehensive income (Note 10)	—	—	—	—	207	207
Net income	—	—	—	6,227	—	6,227
Balance at June 30, 2023	46,409	$46	$950,626	$(142,524)	$(173)	$807,975

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.